Merit Medical Systems Inc

Aktienanalyse zu Merit Medical Systems Inc (MMSI)

$86.240

-6.606 (-7.66%)Zum Schluss

Loading chart…
Hoch
92.445
Eröffnung
91.000
Volumengewichteter Durchschnittskurs
87.56
Volumen
1.80M
Marktkap.
4.85B
Tief
84.000
Umsatz
157.97M
EV/EBITDA, TTM
15.18

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

www.merit.com

KI-Analyse of Merit Medical Systems Inc (MMSI)

Kaufen

Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a 9.5% year-over-year revenue growth in Q2 2026, with total revenue reaching $418.8 million. Additionally, the forward P/E ratio of 18.94 suggests potential for growth compared to its current price of $93.30. However, the risk of insider selling has increased by 1341.20% over the last month, which could indicate potential concerns about future performance.

Analystenbewertungen (9)

+21.32% Aufwärtspotenzial
Kaufen
8 Kaufen
1 Halten
0 Verkaufen
Aktuell: 86.24
Tief
90.00
Durchschnitt
104.63
Hoch
122.00

Barrington

2026-10-30

Kursziel

$116

Überdurchschnittlich

JPMorgan

2026-10-30

Kursziel

$110

Übergewichten

Canaccord

2026-10-30

Kursziel

$121

Kaufen

BTIG

2026-10-30

Kursziel

$110

Kaufen

Needham

2026-10-30

Kursziel

$106

Kaufen

Bewertungskennzahlen

Das aktuelle erwartete KGV von Merit Medical Systems Inc (MMSI) beträgt 20.33, verglichen mit dem 5-Jahres-Durchschnitt von 24.05.

Erwartetes KGV

Unterbewertet
5J-Durchschnitt P/E
24.05
Aktuelles P/E
20.33
Überbewertet
27.39
Unterbewertet
20.71

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
16.84
Aktuelles EV/EBITDA
15.18
Überbewertet
19.05
Unterbewertet
14.62

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
3.26
Aktuelles P/S
3.17
Überbewertet
3.74
Unterbewertet
2.79

Alphio-AI-Kursszenarien für MMSI

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%MMSI

$115.59

Szenariopreis

B

Basis

Basis · 50%MMSI

$110.74

Szenariopreis

B

Bärisch

Bärisch · 25%MMSI

$87.37

Szenariopreis

Whales, die MMSI halten

A

American Capital Management, Inc.

+ HältMMSI

+1.56%

3-Monats-Rendite

W

Westwood Management Corp.

+ HältMMSI

-1.10%

3-Monats-Rendite

J

J. Goldman & Co., L.P.

+ HältMMSI

-2.14%

3-Monats-Rendite

M

Maverick Capital, Ltd.

+ HältMMSI

-4.41%

3-Monats-Rendite

C

Conestoga Capital Advisors, LLC

+ HältMMSI

-7.87%

3-Monats-Rendite

O

Oberweis Asset Management, Inc.

+ HältMMSI

-8.47%

3-Monats-Rendite

MMSI FAQ – beantwortet von Alphio AI

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a 9.5% year-over-year revenue growth in Q2 2026, with total revenue reaching $418.8 million. Additionally, the forward P/E ratio of 18.94 suggests potential for growth compared to its current price of $93.30. However, the risk of insider selling has increased by 1341.20% over the last month, which could indicate potential concerns about future performance.

9 analysts cover MMSI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 104.63.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln